MIRA INFORM
REPORT
|
Report Date : |
11.04.2012 |
IDENTIFICATION DETAILS
|
Name : |
ZACH SYSTEM SPA |
|
|
|
|
Registered Office : |
Via Lillo Del Duca 10, Bresso, 20091 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
13.06.2006 |
|
|
|
|
Com. Reg. No.: |
05341840964 |
|
|
|
|
Legal Form : |
Public Subsidiary Company |
|
|
|
|
Line of Business : |
Subject is engaged in developing, manufacturing and marketing of bulk active
ingredients and advanced intermediates for custom synthesis |
|
|
|
|
No. of Employees
: |
269 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Italy |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
Zach System SpA
Via Lillo Del Duca 10
Bresso, 20091
Italy
Tel: 392665241
Fax: +39 0266 524979
Web: www.zachsystem.com
Synthesis
Employees: 269
Company Type: Public Subsidiary
Corporate Family: 7
Companies
Ultimate Parent: ZAMBON COMPANY SPA
Incorporation Date:
13-Jun-2006
Financials in: USD
(millions)
Fiscal Year End:
31-Dec-2010
Reporting Currency: Euro
Annual Sales: 102.3
Total Assets: 145.0
Business Description
ZaCh System S.p.A.
(ZaCh) is a biotechnology company, engaged in developing, manufacturing and
marketing of bulk active ingredients and advanced intermediates for custom
synthesis. It is engaged in providing complementary services and expertise of
chemical processes. ZaCh provides services for developing products ranging from
chemicals to pharmaceuticals, synthesis to packaging and others. Its
proprietary patents in process chemistry range from asymmetric transformation
and resolution to solid state analysis and control, the multistep synthesis of
complex APIs and separation and purification. ZaCh operates three multipurpose
manufacturing facilities in Lonigo, Italy; Avrille, France; and La Porte, the
US. The company through PPG's fine chemicals business provides extended
production technologies to the customers. ZaCh is a subsidiary of Zambon
Company s.p.a. The company is headquartered in Milano, Italy.
Industry
Industry Biotechnology and Drugs
ANZSIC 2006: 1841 - Human
Pharmaceutical and Medicinal Product Manufacturing
NACE 2002: 2441 - Manufacture
of basic pharmaceutical products
NAICS 2002: 32541 -
Pharmaceutical and Medicine Manufacturing
UK SIC 2003: 2441 - Manufacture
of basic pharmaceutical products
US SIC 1987: 2833 - Medicinal
Chemicals and Botanical Products
Key Executives
|
Name |
Title |
|
Paolo Piatesi |
President |
|
Elena Emilia Zambon |
Vice President |
|
Fabio Bassan |
Executive |
|
Luciano Balbo |
Member of the board |
|
Roberto Emilio Consonni |
Member of the board |
news
|
Title |
Date |
|
Australia Patent: Zach System Files
Application for 'Process for preparing Cinacalcet' |
2-Mar-2012 |
|
Australia Patent: ZaCh System Files
Application for 'Process for preparing Nebivolol' |
27-Dec-2011 |
|
Australia Patent: Zach System Files
Application for 'Process for preparing Cinacalcet hydrochloride' |
19-Jul-2011 |
|
Australia Patent: Zach System Files Application
for 'Process for preparing olopatadine and/or a pharmaceutically acceptable
salt thereof' |
14-Jul-2011 |
|
Australia Patent: Zach System Files
Application for 'Method for preparing nebivolol' |
25-May-2011 |
Registered No.(ITA): 05341840964
1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7550783
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.7454064
Corporate Overview
Location
Via Lillo Del Duca 10
Bresso, 20091
Italy
Tel: 392665241
Fax: +39 0266 524979
Web: www.zachsystem.com
Sales EUR(mil): 77.2
Assets EUR(mil): 108.1
Employees: 269
Fiscal Year End: 31-Dec-2010
Industry: Biotechnology
and Drugs
Incorporation Date: 13-Jun-2006
Company Type: Public
Subsidiary
Quoted Status: Not
Quoted
Registered No.(ITA): 05341840964
President: Paolo
Piatesi
Contents
· Industry Codes
· Business Description
· Financial Data
· Key Corporate Relationships
Industry Codes
ANZSIC 2006 Codes:
1841 - Human Pharmaceutical and Medicinal Product Manufacturing
NACE 2002 Codes:
2441 - Manufacture of basic pharmaceutical products
NAICS 2002 Codes:
32541 - Pharmaceutical and Medicine Manufacturing
US SIC 1987:
2833 - Medicinal Chemicals and Botanical Products
UK SIC 2003:
2441 - Manufacture of basic pharmaceutical products
Business
Description
ZaCh System S.p.A.
(ZaCh) is a biotechnology company, engaged in developing, manufacturing and
marketing of bulk active ingredients and advanced intermediates for custom
synthesis. It is engaged in providing complementary services and expertise of
chemical processes. ZaCh provides services for developing products ranging from
chemicals to pharmaceuticals, synthesis to packaging and others. Its
proprietary patents in process chemistry range from asymmetric transformation
and resolution to solid state analysis and control, the multistep synthesis of
complex APIs and separation and purification. ZaCh operates three multipurpose
manufacturing facilities in Lonigo, Italy; Avrille, France; and La Porte, the
US. The company through PPG's fine chemicals business provides extended
production technologies to the customers. ZaCh is a subsidiary of Zambon
Company s.p.a. The company is headquartered in Milano, Italy.
More Business
Descriptions
Zach System SpA is
primarily engaged in production of medicinally active substances to be used for
their pharmacological properties in the manufacture of medicaments; and
processing of blood. This class also includes: manufacture of chemically pure
sugars; and processing of glands and manufacture of extracts of glands, etc.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
Corporate Family |
Corporate
Structure News: |
|
|
Zach System SpA |
|
Zach System SpA |
|
|
|
|
|
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
ZAMBON COMPANY SPA |
Parent |
|
|
|
|
|
|
|
Zambon SpA |
Subsidiary |
Bresso, Milano |
Italy |
Biotechnology and Drugs |
222.9 |
299 |
|
|
Zambon Italia SRL |
Subsidiary |
Bresso, Milano |
Italy |
Personal and Household Products |
138.7 |
236 |
|
|
Zambon Gesellschaft mit
beschränkter Haftung |
Subsidiary |
Planegg, Bayern |
Germany |
Biotechnology and Drugs |
|
|
|
|
Zach System SpA |
Subsidiary |
Bresso |
Italy |
Biotechnology and Drugs |
102.3 |
299 |
|
|
Zambon Immobiliare SpA |
Subsidiary |
Bresso, Milano |
Italy |
Business Services |
5.0 |
10 |
|
|
Zetacube SRL |
Subsidiary |
Bresso, Milano |
Italy |
Biotechnology and Drugs |
0.6 |
2 |
|
Competitors Report
|
Company Name |
Location |
Employees |
Ownership |
|
Abc Farmaceutici SpA |
Ivrea, Italy |
95 |
Public |
|
Archimica Srl |
Origgio, Italy |
211 |
Private |
|
Geymonat SpA |
Catania, Italy |
64 |
Public |
|
Laboratori Guidotti SpA |
Pisa, Italy |
475 |
Public |
|
Molteni Farmaceutici |
Scandicci, Italy |
169 |
Private |
Executive report
|
Board of Directors |
|
|
|
|
|||
|
Member of the board |
Director/Board Member |
|
|||
|
Member of the board |
Director/Board Member |
|
|||
|
Member of the board |
Director/Board Member |
|
|||
|
Member of the board |
Director/Board Member |
|
|||
|
Member of the board |
Director/Board Member |
|
|||
|
Member of the board |
Director/Board Member |
|
|
Executives |
|
|
|
|
|||
|
President |
President |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Executive |
Other |
|
|||
|
Vice President |
Other |
|
Press release
Zach System Files
Patent Application for Method for Preparing Nebivolol
Indian Patent News
24 February 2012
[What follows is
the full text of the article.]
New Delhi, Feb. 24
-- France based Zach System filed patent application for method for preparing
nebivolol. The inventors are Derrien Yvon, Chenard Eric and Burgos Alain.
Zach System filed
the patent application on March 3, 2011. The patent application number is
1521/DELNP/2011 A. The international classification number is C07D.
According to the
Controller General of Patents, Designs & Trade Marks, "The invention
relates to a method for preparing nebivolol, and more particularly to an
improved method for the synthesis of an alphahaloketone of the formula, which
is a key intermediate in the preparation of nebivolol."
About the Company
ZaCh System SpA
produces fine chemicals and pharmaceutical ingredients. The company also
provides custom synthesis services, APIs, and intermediates. ZaCh System S.p.A.
was founded in 2007 and is based in Bresso, Italy.
Zach System S.p.A.
Files Patent Application for Process for the Preparation of Clopidogrel Hydrogen
Sulfate Crystalline Form I
Indian Patent News
02 September 2011
[What follows is
the full text of the article.]
New Delhi, Sept. 2
-- Italy based Zach System S.p.A. filed patent application for process for the
preparation of clopidogrel hydrogen sulfate crystalline Form I. The inventors
are Soriato Giorgio, Brescello Roberto, Urbani Daniele and Cotarca Livius.
Zach System S.p.A.
filed the patent application on Dec. 24, 2010. The patent application number is
8441/CHENP/2010 A. The international classification number is C07D495/04.
According to the
Controller General of Patents, Designs & Trade Marks, "The present
invention relates to a process for the preparation of clopidogrel and, more particularly,
to an improved process for the preparation of clopidogrel hydrogen sulfate
crystalline Form I by addition of dilute sulfuric acid to a solution of
clopidogrel free base in butyl acetate."
About the Company
ZaCh System S.p.A.
is a fine chemicals company dedicated not only to providing its customers with
fast, cost-effective quality custom synthesis services, APIs and intermediates
but also to supporting them with extensive process development expertise.
ZaCh System S.p.A.
Files Patent Application for Process for Preparing Nebivolol
Indian Patent News
06 June 2011
[What follows is the full text of the article.]
New Delhi, June 6
-- Italy based ZaCh System S.p.A. filed patent application for process for
preparing nebivolol. The inventors are Volpicelli Raffaella, Maragni Paolo,
Massaccesi Franco, Munari Ilaria, Cotarca Livius and Foletto Johnny.
ZaCh System S.p.A.
filed the patent application on Sept. 29, 2010. The patent application number
is 6140/CHENP/2010 A. The international classification number is C07D311/58.
According to the
Controller General of Patents, Designs & Trade Marks, "The present
invention relates to a process for preparing Nebivolol and, more particularly,
to a method for stereoselective reduction of an alpha-haloketone of formula
intermediate useful for the preparation of Nebivolol."
About the Company
ZaCh System S.p.A. produces fine chemicals and pharmaceutical
ingredients. The company also provides custom synthesis services, APIs, and
intermediates. ZaCh System S.p.A. was founded in 2007 and is based in Bresso,
Italy. The company has facilities in Lonigo, Italy; Avrille, France; and
LaPorte, Texas. ZaCh System S.p.A. is a subsidiary of Zambon Company S.p.A.
Zach System S.P.A
Files Patent Application for a Process for the Purification of Gabapentin
Indian Patent News
22 April 2011
[What follows is
the full text of the article.]
New Delhi, April
22 -- Italy based Zach System S.P.A filed patent application for a process for
the purification of gabapentin. The inventors are Giovanetti Roberto, Nicoli
Andrea and Cotarca Livius.
Zach System S.P.A
filed the patent application on July 16, 2007. The patent application number is
3122/CHENP/2007 A. The international classification number is C07C227/40.
According to the Controller
General of Patents, Designs & Trade Marks, "The present invention
relates to a process for the purification of gabapentin. The process relates to
the addition of hydrochloric acid to an aqueous solution or suspension of
gabapentin, before, during or after the concentration step of that solution,
and the subsequent slurry of the gabapentin by the addition of an alcoholic
solvent. The so obtained gabapentin has an high purity degree and, in
particular, is characterized by a low content of lactam."
About the Company
ZaCh System S.p.A.
produces fine chemicals and pharmaceutical ingredients. The company also
provides custom synthesis services, APIs, and intermediates. ZaCh System S.p.A.
was founded in 2007 and is based in Bresso, Italy. The company has facilities
in Lonigo, Italy; Avrill, France; and LaPorte, Texas. ZaCh System S.p.A. is a
subsidiary of Zambon Company S.p.A.
Zach System S.p.A.
Files Patent Application for Process for the Preparation of Carvedilol and Its
Enantiomers
Indian Patent News
19 April 2011
[What follows is the full text of the article.]
New Delhi, April
19 -- Italy based Zach System S.p.A. filed patent application for process for
the preparation of carvedilol and its enantiomers. The inventors are Trepat
Guixer Elisenda, Munoz Alvarez Anna, Pomares Marco Marta and Marquillas
Olondriz Francisco.
Zach System S.p.A.
filed the patent application on Nov. 6, 2007. The patent application number is
2478/CHENP/2007 A. The international classification number is C07D209/88.
According to the
Controller General of Patents, Designs & Trade Marks, "The present
invention relates to a process for the preparation of carvedilol as well as of
the optically active R and S enantiomers thereof and of mixtures of these
enantiomers and, more particularly, relates to an improved process for the
preparation of carvedilol and its enantiomers characterized by the use of ethyl
acetate as reaction solvent."
About the Company
ZaCh System S.p.A. produces fine chemicals and pharmaceutical
ingredients. The company also provides custom synthesis services, APIs, and
intermediates. ZaCh System S.p.A. was founded in 2007 and is based in Bresso,
Italy. The company has facilities in Lonigo, Italy; Avrill, France; and
LaPorte, Texas. ZaCh System S.p.A. is a subsidiary of Zambon Company S.p.A.
Annual Profit & Loss
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.755078 |
0.719047 |
0.683679 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Total income |
108.3 |
96.0 |
133.3 |
|
Net sales |
102.3 |
99.3 |
133.3 |
|
Other operating income |
0.9 |
2.5 |
0.4 |
|
Raw materials and consumables employed |
52.0 |
41.3 |
57.9 |
|
Other expenses |
27.5 |
25.9 |
34.5 |
|
Total payroll costs |
22.6 |
21.5 |
23.1 |
|
Fixed asset depreciation and amortisation |
11.6 |
13.0 |
13.9 |
|
Other operating costs |
1.5 |
1.2 |
1.0 |
|
Net operating
income |
-6.8 |
-6.9 |
2.9 |
|
Total financial
income |
0.7 |
0.5 |
3.4 |
|
Total expenses |
0.6 |
2.1 |
5.9 |
|
Profit before tax |
-6.8 |
-8.4 |
0.5 |
|
Extraordinary result |
-1.8 |
-38.1 |
-16.7 |
|
Profit after extraordinary items and
before tax |
-8.6 |
-46.5 |
-16.2 |
|
Total taxation |
-1.4 |
-1.7 |
-1.6 |
|
Net loss |
7.2 |
44.8 |
14.7 |
Annual Balance
Sheet
Financials in: USD (mil)
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745406 |
0.696986 |
0.719399 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Total
stockholders equity |
42.2 |
31.4 |
26.4 |
|
Provision for risks |
0.8 |
3.6 |
5.8 |
|
Provision for pensions |
4.0 |
4.5 |
4.6 |
|
Other long-term liabilities |
64.4 |
89.8 |
85.6 |
|
Trade creditors |
21.9 |
18.3 |
23.9 |
|
Other current liabilities |
11.6 |
15.9 |
55.5 |
|
Accruals and deferred income |
0.0 |
0.1 |
0.6 |
|
Total current
liabilities |
33.6 |
34.3 |
80.0 |
|
Total
liabilities (including net worth) |
145.0 |
163.5 |
202.4 |
|
Intangibles |
0.3 |
0.0 |
0.3 |
|
Buildings |
8.8 |
9.4 |
8.7 |
|
Total tangible
fixed assets |
43.6 |
48.1 |
51.2 |
|
Long-term investments |
29.6 |
32.7 |
54.5 |
|
Total financial
assets |
29.7 |
32.8 |
54.6 |
|
Total
non-current assets |
73.6 |
80.9 |
106.1 |
|
Finished goods |
25.1 |
21.2 |
26.3 |
|
Net stocks and work in progress |
32.9 |
30.3 |
36.1 |
|
Trade debtors |
15.9 |
17.1 |
19.3 |
|
Other receivables |
21.9 |
31.6 |
34.9 |
|
Cash and liquid assets |
0.5 |
3.5 |
5.9 |
|
Accruals |
0.2 |
0.0 |
0.0 |
|
Total current
assets |
71.4 |
82.6 |
96.3 |
|
Total assets |
145.0 |
163.5 |
202.4 |
Annual Ratios
Financials in: USD (mil)
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745406 |
0.696986 |
0.719399 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Current ratio |
2.10 |
2.40 |
1.20 |
|
Quick ratio |
1.20 |
1.50 |
0.80 |
|
Current liabilities to net worth |
0.01% |
0.01% |
0.03% |
|
Sales per employee |
0.29 |
0.27 |
0.33 |
|
Profit per employee |
-0.02 |
-0.12 |
-0.04 |
|
Average wage per employee |
0.06 |
0.06 |
0.06 |
|
Net worth |
42.2 |
31.4 |
26.4 |
|
Number of employees |
269 |
269 |
274 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.51.20 |
|
UK Pound |
1 |
Rs.81.50 |
|
Euro |
1 |
Rs.67.15 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.
s